1. Home
  2. ADAP vs COHN Comparison

ADAP vs COHN Comparison

Compare ADAP & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • COHN
  • Stock Information
  • Founded
  • ADAP 2008
  • COHN 1999
  • Country
  • ADAP United Kingdom
  • COHN United States
  • Employees
  • ADAP N/A
  • COHN N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • ADAP Health Care
  • COHN Finance
  • Exchange
  • ADAP Nasdaq
  • COHN Nasdaq
  • Market Cap
  • ADAP 21.3M
  • COHN 21.6M
  • IPO Year
  • ADAP 2015
  • COHN N/A
  • Fundamental
  • Price
  • ADAP $0.14
  • COHN $10.97
  • Analyst Decision
  • ADAP Hold
  • COHN
  • Analyst Count
  • ADAP 6
  • COHN 0
  • Target Price
  • ADAP $1.02
  • COHN N/A
  • AVG Volume (30 Days)
  • ADAP 139.0M
  • COHN 4.2K
  • Earning Date
  • ADAP 11-12-2025
  • COHN 11-03-2025
  • Dividend Yield
  • ADAP N/A
  • COHN 9.02%
  • EPS Growth
  • ADAP N/A
  • COHN 37.63
  • EPS
  • ADAP N/A
  • COHN 1.14
  • Revenue
  • ADAP $65,084,999.00
  • COHN $133,173,000.00
  • Revenue This Year
  • ADAP N/A
  • COHN N/A
  • Revenue Next Year
  • ADAP $24.70
  • COHN N/A
  • P/E Ratio
  • ADAP N/A
  • COHN $9.65
  • Revenue Growth
  • ADAP N/A
  • COHN 78.63
  • 52 Week Low
  • ADAP $0.04
  • COHN $6.10
  • 52 Week High
  • ADAP $0.96
  • COHN $13.25
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 56.57
  • COHN 39.42
  • Support Level
  • ADAP $0.12
  • COHN $10.90
  • Resistance Level
  • ADAP $0.16
  • COHN $11.46
  • Average True Range (ATR)
  • ADAP 0.03
  • COHN 0.31
  • MACD
  • ADAP 0.00
  • COHN -0.01
  • Stochastic Oscillator
  • ADAP 39.87
  • COHN 14.12

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: